Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental ...

Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...

This Rare Disease Day, observed on Feb. 28 worldwide, the American Kidney Fund is committed to improving the understanding of ...

Healthy people can usually eat higher protein safely, but diets high in animal proteins may raise risks or crowd out other ...

Data from Boehringer Ingelheim’s Phase II apecotrep study was published in The Lancet and presented at the 2025 ASN’s Kidney Week ...

When formulating diets for sows it is possible to reduce dietary protein by decreasing soybean meal inclusion and increase ...

Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...

A new study shows that reducing dietary protein slowed liver tumor growth and extended survival in mice by lowering toxic ...

, Jan. 26 -- protein diets have become increasingly popular for weight loss and muscle building, but many people experience bloating, fatigue, constipation, or discomfort after upping their protein ...

Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental ...

Patients with immunoglobin A nephropathy who reached complete remission of proteinuria with sparsentan had greater eGFR ...